Pinned post
When we started @Xaira_Thera we were clear that for molecular AI to make a difference for patients, it had to be able to address the hardest and most clinically relevant problems; those that traditional methods haven't been able to solve.
For that, we've been building X-Design, bringing together top-tier research, engineering and wet lab capabilities into a model focused on designing clinically progressible molecules.
Today, we showcase just some of that work; designing functional, progressible antibodies for our "undruggable" XA-4 program de novo.
bit.ly/4hAOhEW
For that, we've been building X-Design, bringing together top-tier research, engineering and wet lab capabilities into a model focused on designing clinically progressible molecules.
Today, we showcase just some of that work; designing functional, progressible antibodies for our "undruggable" XA-4 program de novo.
bit.ly/4hAOhEW
www.xaira.com De Novo Design of Progressable Antibodies to Therapeutic Targets | Xaira Therapeutics De Novo Design of Progressable Antibodies to Therapeutic Targets. News and insights from Xaira Therapeutics on AI-driven drug discovery and development. 
